What is the AHK-Cu dosage, and how is a vial mixed?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds AHK-Cu and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    The searches returned no approved label or human dosing trial for AHK-Cu; the one registry entry, NCT07888595 (an estimated 48 participants), lists AHK-Cu as one of five peptides in a topical serum applied at approximately 1-3 mg/mL to skin sites, not an injection dose.1

    The guide's example

    1,000 mcg of AHK-Cu from a 50 mg vial mixed with 2 mL is 4 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water3 mL of water
    50 mg50 mg/mL: 1,000 mcg is 2 units, 2,000 mcg is 4 units, 3,000 mcg is 6 units25 mg/mL: 1,000 mcg is 4 units, 2,000 mcg is 8 units, 3,000 mcg is 12 units16.667 mg/mL: 1,000 mcg is 6 units, 2,000 mcg is 12 units, 3,000 mcg is 18 units

    A 50 mg vial in syringe units

    One lab certificate for a vendor batch reports AHK-Cu as 50mg vials of 3mL.2 The same certificate describes the product as a lyophilized puck, that is a powder.2 No label or maker's leaflet saved states which water to add or how much, so the table is arithmetic and not a mixing instruction. The doses in the table and the worked example are round amounts for the arithmetic only: no label or human trial located gives an AHK-Cu injection dose, and the registry's approximately 1-3 mg/mL is the concentration of a topical serum of five peptides, not a dose.1

    1,000 mcg of AHK-Cu from a 50 mg vial mixed with 2 mL is 4 units on a U-100 syringe.

    The calculator is at the top of the page

    Dose, schedule and route in the sources

    FDA's page on substances in compounding that may present significant safety risks lists the related copper peptide GHK-Cu (for injectable routes of administration), noting limited data in humans, and does not name AHK-Cu.3 The registry study NCT07888595 enrols an estimated 48 people in a single group, with no separate dose arms.1 Its topical serum holds five small peptides together (GHK-Cu, AHK-Cu, Epitalon, PGP and CLV), applied at approximately 1-3 mg/mL to defined skin sites, so AHK-Cu is not tested alone, and its outcomes have a 4-week time frame.1 That entry states that its systemic component gives agents orally or subcutaneously, and the agents it lists are not AHK-Cu.1

    The searches returned no dosing schedule, cycle length or stepping from a label or human trial. They returned no injection route or site either.

    How AHK-Cu is stored

    The searches returned no storage condition, before or after mixing, from a label, a trial or the FDA page. They returned no stability data for a mixed vial.

    Frequently asked questions

    Does AHK-Cu come in other vial strengths?

    The one strength located is 50mg, from one vendor batch certificate; a search for a larger vial found none.2

    What concentrations did the hair-follicle study test?

    The 2007 laboratory study by Pyo and colleagues tested AHK-Cu at 10(-12) to 10(-9) M in human hair follicles ex vivo and cultured dermal papilla cells.4 That is a cell and tissue result, not a human dose, and the study gave AHK-Cu to no human participants.4

    References

    1. ClinicalTrials.gov. NCT07888595: Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks. 2026. clinicaltrials.gov
    2. PS Peptides (certificate of analysis). North American Diagnostics. pspeptides.com
    3. US FDA. Substances in Compounding that May Present Significant Safety Risks. 2026. fda.gov
    4. Archives of Pharmacal Research (PubMed). The effect of tripeptide-copper complex on human hair growth in vitro. 2007. pubmed.ncbi.nlm.nih.gov